Therapies for multiple sclerosis: Translational achievements and outstanding needs

Trends in Molecular Medicine

Volumn 19, Issue 5, 2013, Pages 309-319

  Haghikia, Aiden ^a,b   Hohlfeld, Reinhard ^c   Gold, Ralf ^b   Fugger, Lars ^a,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Dimethyl fumarate; Glatiramer acetate; IFN ; Monoclonal antibodies; Multiple sclerosis; TNF receptor 1

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; SIMVASTATIN;

ALOPECIA; AMENORRHEA; ANXIETY DISORDER; ARTHRALGIA; ATRIOVENTRICULAR BLOCK; BACKACHE; BRADYCARDIA; CEREBROSPINAL FLUID; CHILL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; EMPYEMA; ENCEPHALITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; HEART LEFT VENTRICLE FAILURE; HERPES SIMPLEX; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; MELANOMA; MENTAL INSTABILITY; MESENTERIC ARTERY OCCLUSION; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PRURITUS; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN INFECTION; THYROID CANCER; THYROID DISEASE; UPPER RESPIRATORY TRACT INFECTION; VARICELLA ZOSTER VIRUS; VOMITING; WHITE MATTER;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INDIVIDUALIZED MEDICINE; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS;

EID: 84877118165     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.03.004     Document Type: Review

References (81)

1. Polman C.H., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
2. Tremlett H., et al. New perspectives in the natural history of multiple sclerosis. Neurology 2010, 74:2004-2015.
3. Popescu B.F., Lucchinetti C.F. Pathology of demyelinating diseases. Annu. Rev. Pathol. 2012, 7:185-217.
4. Hasan K.M., et al. Multimodal quantitative magnetic resonance imaging of thalamic development and aging across the human lifespan: implications to neurodegeneration in multiple sclerosis. J. Neurosci. 2011, 31:16826-16832.
5. Marik C., et al. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?. Brain 2007, 130:2800-2815.
6. Mahad D.J., et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009, 132:1161-1174.
7. Attfield K.E., et al. Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis. Immunol. Rev. 2012, 248:10-22.
8. Lucchinetti C.F., et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 2011, 365:2188-2197.
9. Gold R., et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 2012, 367:1098-1107.
10. Tumani H., et al. Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann. Neurol. 2011, 70:520. author reply 521.
11. Miller D.H., et al. Clinically isolated syndromes. Lancet Neurol. 2012, 11:157-169.
12. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009, 65:239-248.
13. Lalive P.H., et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011, 25:401-414.
14. Prinz M., et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28:675-686.
15. Comabella M., et al. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin. Immunol. 2009, 130:145-150.
16. Killestein J., Polman C.H. Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat. Rev. Neurol. 2011, 7:221-228.
17. Kinkel R.P., et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch. Neurol. 2012, 69:183-190.
18. O'Connor P., et al. 250 microg or 500 microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009, 8:889-897.
19. Shirani A., et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012, 308:247-256.
20. Conway D., Cohen J.A. Combination therapy in multiple sclerosis. Lancet Neurol. 2010, 9:299-308.
21. Havrdova E., et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult. Scler. 2009, 15:965-976.
22. Sorensen P.S., et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011, 10:691-701.
23. Lindsey J., et al. The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: design and baseline characteristics. Mult. Scler. Relat. Disord. 2012, 1:81-86.
24. Hartung H.P., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
25. Edan G., et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J. Neurol. Neurosurg. Psychiatry 2011, 82:1344-1350.
26. Ransohoff R.M. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 2012, 15:1074-1077.
27. Polman C.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910.
28. Rudick R.A., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:911-923.
29. Wenning W., et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N. Engl. J. Med. 2009, 361:1075-1080.
30. Linda H., et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med. 2009, 361:1081-1087.
31. Bloomgren G., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2012, 366:1870-1880.
32. Carson K.R., et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009, 10:816-824.
33. Ransohoff R.M. Natalizumab and PML. Nat. Neurosci. 2005, 8:1275.
34. + T cells in cerebral perivascular spaces due to natalizumab. Arch. Neurol. 2008, 65:1596-1603.
35. Sorensen P.S., et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult. Scler. 2011, 17:1074-1078.
36. O'Connor P.W., et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011, 76:1858-1865.
37. Havrdova E., et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009, 8:254-260.
38. Kappos L., et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011, 10:745-758.
39. Gorelik L., et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol. 2010, 68:295-303.
40. Miller D.H., et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012, 11:131-139.
41. Schwab S.R., Cyster J.G. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol. 2007, 8:1295-1301.
42. Miron V.E., et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am. J. Pathol. 2010, 176:2682-2694.
43. Cohen J.A., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:402-415.
44. Kappos L., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387-401.
45. Fox R.J., et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 2012, 367:1087-1097.
46. Ghoreschi K., et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med. 2011, 208:2291-2303.
47. Linker R.A., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
48. Giovannoni G., et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:416-426.
49. Comi G., et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 2012, 366:1000-1009.
50. O'Connor P., et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 2011, 365:1293-1303.
51. Segal B.M., et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008, 7:796-804.
52. Gregory A.P., et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012, 488:508-511.
53. Barr T.A., et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 2012, 209:1001-1010.
54. Hawker K., et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009, 66:460-471.
55. Kappos L., et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
56. Coles A.J., et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008, 359:1786-1801.
57. Coles A.J., et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1829-1839.
58. Cohen J.A., et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012, 380:1819-1828.
59. Jones J.L., et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 2009, 119:2052-2061.
60. Wuest S.C., et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 2011, 17:604-609.
61. Wynn D., et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010, 9:381-390.
62. van Oosten B.W., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534.
63. Corvol J.C., et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann. Neurol. 2011, 69:111-118.
64. Wheeler H.E., et al. Cancer pharmacogenomics: strategies and challenges. Nat. Rev. Genet. 2013, 14:23-34.
65. Hedstrom A.K., et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011, 134:653-664.
66. Barkhof F., et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat. Rev. Neurol. 2011, 8:13-21.
67. Reyes N.A., et al. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J. Clin. Invest. 2010, 120:3673-3679.
68. Cudkowicz M., et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat. Med. 2011, 17:1652-1656.
69. Vergo S., et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 2011, 134:571-584.
70. Arun T., et al. Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride. Brain 2013, 136:106-115.
71. Waxman S.G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis - current status. Nat. Clin. Pract. Neurol. 2008, 4:159-169.
72. Goodman A.D., et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann. Neurol. 2010, 68:494-502.
73. Mi S., et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 2007, 13:1228-1233.
74. Uccelli A., et al. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol. 2011, 10:649-656.
75. Connick P., et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012, 11:150-156.
76. Paty D.W., Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:662-667.
77. Jacobs L.D., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 1996, 39:285-294.
78. Group P.S. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352:1498-1504.
79. Mikol D.D., et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008, 7:903-914.
80. Comi G., et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 2001, 49:290-297.
81. Hauser S.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.